Page 120 - 《中国药房》2022年12期

fication of genetic variations of the human organic cation Curr Pharm Des，2017，23（17）：2532-2550.
transporter hOCT1 and their functional consequences[J]. [33] HE L，WONDISFORD F E. Metformin action：concentra-
Pharmacogenetics，2002，12（8）：591-595. tions matter[J]. Cell Metab，2015，21（2）：159-162.
[20] ITODA M，SAITO Y，MAEKAWA K，et al. Seven novel [34] XIA L，ENGEL K，ZHOU M Y，et al. Membrane localiza-
single nucleotide polymorphisms in the human SLC22A1 tion and pH-dependent transport of a newly cloned orga-
gene encoding organic cation transporter 1（OCT1）[J]. nic cation transporter（PMAT）in kidney cells[J]. Am J
Drug Metab Pharmacokinet，2004，19（4）：308-312. Physiol Renal Physiol，2007，292（2）：F682-F690.
[21] BECKER M L，VISSER L E，VAN SCHAIK R H N，et al. [35] BACHMAKOV I，GLAESER H，FROMM M F，et al. In-
Interaction between polymorphisms in the OCT1 and teraction of oral antidiabetic drugs with hepatic uptake
MATE1 transporter and metformin response[J]. Pharmaco- transporters：focus on organic anion transporting polypep-
genet Genomics，2010，20（1）：38-44. tides and organic cation transporter 1[J]. Diabetes，2008，
[22] WRÓBEL M P，MAREK B，KAJDANIUK D，et al. Met- 57（6）：1463-1469.
formin：a new old drug[J]. Endokrynol Pol，2017，68（4）： [36] DING Y，JIA Y Y，SONG Y，et al. The effect of lansopra-
482-496. zole，an OCT inhibitor，on metformin pharmacokinetics in
[23] ITO S，KUSUHARA H，KUROIWA Y，et al. Potent and healthy subjects [J]. Eur J Clin Pharmacol，2014，70（2）：
specific inhibition of mMate1-mediated efflux of type Ⅰ 141-146.
organic cations in the liver and kidney by pyrimethamine[J]. [37] NIES A T，HOFMANN U，RESCH C，et al. Proton pump
J Pharmacol Exp Ther，2010，333（1）：341-350. inhibitors inhibit metformin uptake by organic cation
[24] STOCKER S L，MORRISSEY K M，YEE S W，et al. The transporters（OCTs）[J]. PLoS One，2011，6（7）：e22163.
effect of novel promoter variants in MATE1 and MATE2 [38] KIM A，CHUNG I，YOON S H，et al. Effects of proton
on the pharmacokinetics and pharmacodynamics of met- pump inhibitors on metformin pharmacokinetics and phar-
formin[J]. Clin Pharmacol Ther，2013，93（2）：186-194. macodynamics[J]. Drug Metab Dispos，2014，42（7）：
[25] CHOI J H，YEE S W，RAMIREZ A H，et al. A common 1174-1179.
5′-UTR variant in MATE2-K is associated with poor [39] STAUD F，CERVENY L，AHMADIMOGHADDAM D，
response to metformin[J]. Clin Pharmacol Ther，2011，90 et al. Multidrug and toxin extrusion proteins（MATE/
（5）：674-684. SLC47）；role in pharmacokinetics[J]. Int J Biochem Cell
[26] TAKANE H，SHIKATA E，OTSUBO K，et al. Polymor- Biol，2013，45（9）：2007-2011.
phism in human organic cation transporters and metfor- [40] MISAKA S，KNOP J，SINGER K，et al. The nonmetabo-
min action[J]. Pharmacogenomics，2008，9（4）：415-422. lized β-blocker nadolol is a substrate of OCT1，OCT2，
[27] SONG I S，SHIN H J，SHIM E J，et al. Genetic variants of MATE1，MATE2-K，and P-glycoprotein，but not of
the organic cation transporter 2 influence the disposition OATP1B1 and OATP1B3[J]. Mol Pharm，2016，13（2）：
of metformin[J]. Clin Pharmacol Ther，2008，84（5）：559- 512-519.
562. [41] SOMOGYI A，STOCKLEY C，KEAL J，et al. Reduction
[28] WANG Z J，YIN O Q P，TOMLINSON B，et al. OCT2 of metformin renal tubular secretion by cimetidine in
polymorphisms and in-vivo renal functional consequence： man[J]. Br J Clin Pharmacol，1987，23（5）：545-551.
studies with metformin and cimetidine[J]. Pharmacogenet [42] CHO S K，CHUNG J Y. The MATE1 rs2289669 polymor-
Genomics，2008，18（7）：637-645. phism affects the renal clearance of metformin following
[29] 玛依拉·艾则孜.维吾尔族 SLC22A2 多态性及 rs316019 ranitidine treatment[J]. Int J Clin Pharmacol Ther，2016，
突变对二甲双胍药代学、药效学的影响[D].乌鲁木齐：新 54（4）：253-262.
疆医科大学，2019. [43] HIBMA J E，ZUR A A，CASTRO R A，et al. The effect of
[30] MOON S J，OH J，LEE S H，et al. Effect of plasma mem- famotidine，a MATE1-selective inhibitor，on the pharma-
brane monoamine transporter genetic variants on pharma- cokinetics and pharmacodynamics of metformin[J]. Clin
cokinetics of metformin in humans[J]. Transl Clin Pharma- Pharmacokinet，2016，55（6）：711-721.
col，2018，26（2）：79-85. [44] GRÜN B，KIESSLING M K，BURHENNE J，et al. Trime-
[31] CHOI M K，SONG I S. Genetic variants of organic cation thoprim-metformin interaction and its genetic modulation
transporter 1（OCT1）and OCT2 significantly reduce lami- by OCT2 and MATE1 transporters[J]. Br J Clin Pharma-
vudine uptake[J]. Biopharm Drug Dispos，2012，33（3）： col，2013，76（5）：787-796.
170-178. [45] JAYASAGAR G，KRISHNAKUMAR M，CHANDRASEKHAR
[32] MARKOWICZ-PIASECKA M，HUTTUNEN K M， K，et al. Effect of cephalexin on the pharmacokinetics of
MATEUSIAK L，et al. Is metformin a perfect drug? Up- metformin in healthy human volunteers[J]. Drug Metabol
dates in pharmacokinetics and pharmacodynamics[J]. Drug Interact，2002，19（1）：41-48.

·1518 · China Pharmacy 2022 Vol. 33 No. 12 中国药房 2022年第33卷第12期